When was Rivus Pharmaceuticals founded?

Rivus Pharmaceuticals was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Rivus Pharmaceuticals located?

Rivus Pharmaceuticals is headquartered in Charlottesville, United States.

Who is the current CEO of Rivus Pharmaceuticals?

Allen Cunningham of Rivus Pharmaceuticals.

Which legal entities is Rivus Pharmaceuticals associated with?

Rivus Pharmaceuticals is associated with Rivus Pharmaceuticals, Inc.

Is Rivus Pharmaceuticals a funded company?

Rivus Pharmaceuticals is a funded company, having raised a total of $290M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 20, 2021.

When was the latest funding round of Rivus Pharmaceuticals?

Rivus Pharmaceuticals' latest funding was a $***** Series B round on Jan 07, 2025, with participation from 0 investor. Its primary sector is Cardiac and Vascular Disorders. In United States, the Cardiac and Vascular Disorders sector has seen $1.33B in funding in 2026 to date.

Where does Rivus Pharmaceuticals rank among its competitors?

Rivus Pharmaceuticals ranks 49th amongst 524 active competitors, of which 182 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Vor Biopharma, which secured $150M in Dec, 2025.

Who are the top competitors of Rivus Pharmaceuticals?

Rivus Pharmaceuticals' top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Vor Biopharma secured the most recent funding round in December, 2025.

Rivus Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Rivus Pharmaceuticals is a series B company based in Charlottesville (United States), founded in 2019. It operates as a Developer of therapeutics for cardio-metabolic disorders. Rivus Pharmaceuticals has raised $290M in funding from investors like RA Capital Management, Longitude Capital and Medicxi. The company has 524 active competitors, including 182 funded and 121 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Developer of therapeutics for cardio-metabolic disorders. The company's lead candidate HU6 is a controlled metabolic accelerator for the treatment of type 2 diabetes, severe hypertriglyceridemia, non-alcoholic steatohepatitis, and heart failure with preserved ejection fraction.

Website: www.rivuspharma.com/
Social
Email ID: *****@rivuspharma.com

Key Metrics

Founded Year

2019

Location

Charlottesville, United States

Stage

Series B

Total Funding

$290M in 4 rounds

Latest Funding Round

Series B, Jan 07, 2025, $*****

Investors

RA Capital Management & 5 more

Ranked

49^th among 524 active competitors

Similar Companies

Tenaya Therapeutics & 516 more

View Rivus Pharmaceuticals' full profile

Rivus Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rivus Pharmaceuticals, Inc CIN: F7290703 , United States, Active	Mar 12, 2019	-	-	-

Rivus Pharmaceuticals has raised a total funding of $290M over 4 rounds. Its first funding round was on Jun 20, 2021. Rivus Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of Rivus Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2025	2472275	Series B	2894626	3194660	1224110	2531384
Aug 09, 2024	1791248	Series B	4985553	7645886	8835330	4094263
Sep 22, 2022	2884622	Series B	8266870	4554985	RA Capital Management	Bain Capital Life Sciences & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Rivus Pharmaceuticals's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rivus Pharmaceuticals include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Rivus Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Longitude Capital & 16 others	66/100
6th	Carmot 2008, Berkeley (United States), Acquired	Developer of disease-modifying therapies to treat metabolic diseases	$386M	The Column Group, Deep Track Capital & 17 others	66/100
7th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
8th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	65/100
9th	Assembly Biosciences 2005, New York City (United States), Public	Developing novel antivirals to treat serious viral diseases	$700K	Avoro Capital, Armistice Capital & 3 others	65/100
10th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, Leaps by Bayer & 7 others	65/100
49th	Rivus Pharmaceuticals 2019, Charlottesville (United States), Series B	Developer of therapeutics for cardio-metabolic disorders	$290M	Bain Capital Life Sciences, BB Biotech & 4 others	55/100